Home Cart Sign in  
Chemical Structure| 61303-13-7 Chemical Structure| 61303-13-7

Structure of Isoacteoside
CAS No.: 61303-13-7

Chemical Structure| 61303-13-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Isoacteoside is a natural compound isolated and purified from the herb of Pedicularis striata Pall. which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM, compared with those of aminoguanidine (IC50=1,056 μM) and quercetin (IC50=28.4 μM) as positive controls, and exhibits anti-inflammatory effects through blocking TLR4 dimerization.

Synonyms: Isoverbascoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Isoacteoside

CAS No. :61303-13-7
Formula : C29H36O15
M.W : 624.59
SMILES Code : O=C(/C=C/C1=CC=C(O)C(O)=C1)OC[C@H]2O[C@@H](OCCC3=CC=C(O)C(O)=C3)[C@H](O)[C@H]([C@@H]2O)O[C@H](O[C@@H](C)[C@@H]4O)[C@@H]([C@@H]4O)O
Synonyms :
Isoverbascoside
MDL No. :MFCD06798947
InChI Key :FNMHEHXNBNCPCI-QEOJJFGVSA-N
Pubchem ID :6476333

Safety of Isoacteoside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDMs) 20, 40, 80 μM 24 hours To evaluate the inhibitory effect of Isoacteoside on LPS-induced cytokine release, results showed that Isoacteoside significantly suppressed the secretion of TNF-α, IL-6, and IL-1β. Br J Pharmacol. 2017 Sep;174(17):2880-2896
HEK293T cells 80 μM 24 hours To evaluate the effect of Isoacteoside on TLR4 dimerization, results showed that Isoacteoside significantly inhibited LPS-induced TLR4 dimerization. Br J Pharmacol. 2017 Sep;174(17):2880-2896
RAW264.7 macrophages 20, 40, 80 μM 24 hours To evaluate the inhibitory effect of Isoacteoside on LPS-induced inflammatory responses, results showed that Isoacteoside significantly suppressed the expression of COX-2, iNOS, TNF-α, IL-6, and IL-1β. Br J Pharmacol. 2017 Sep;174(17):2880-2896
SH-SY5Y cells 50 μg/mL 24 hours Protected SH-SY5Y cells against Aβ1-42-induced neural damage and restored cell viability Int J Mol Sci. 2017 Apr 24;18(4):895

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice HCC xenograft model Intraperitoneal injection 30 mg/kg Once daily for two weeks The combination of Isoacteoside and sorafenib significantly inhibits tumor growth, showing better efficacy than sorafenib monotherapy. Commun Biol. 2025 Feb 8;8(1):205
BALB/c mice Xylene-induced ear oedema model, LPS-induced endotoxic shock model, and LPS-induced endotoxaemia-associated acute kidney injury (AKI) model Intraperitoneal injection 100 mg·kg-1 (ear oedema and endotoxic shock models); 25, 50, 100 mg·kg-1 (AKI model) Single dose (ear oedema and endotoxic shock models); single dose and observed for 132 hours (endotoxic shock model); single dose and samples collected after 12 hours (AKI model) To evaluate the anti-inflammatory effects of Isoacteoside in vivo, results showed that Isoacteoside significantly inhibited xylene-induced ear oedema, LPS-induced endotoxic death, and protected against LPS-induced acute kidney injury. Br J Pharmacol. 2017 Sep;174(17):2880-2896
Sprague-Dawley rats Aβ1-42-induced Alzheimer's disease model Oral 2.5, 5.0 mg/kg Once daily for 14 days Ameliorated cognitive deficits induced by Aβ1-42, reduced amyloid deposition, and restored central cholinergic and monoaminergic function Int J Mol Sci. 2017 Apr 24;18(4):895

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.60mL

0.32mL

0.16mL

8.01mL

1.60mL

0.80mL

16.01mL

3.20mL

1.60mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories